Advanced Solid Cancers
16
6
8
5
Key Insights
Highlights
Success Rate
63% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
18.8%
3 terminated out of 16 trials
62.5%
-24.0% vs benchmark
0%
0 trials in Phase 3/4
40%
2 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (16)
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
Phase II/III Trial of PRL3-Zumab in Advanced Solid Tumor Patients
Exploratory Clinical Study of Targeted Activated DC and CAR-T Therapy in Advanced Solid Cancers
ADCX-020 for the Treatment of Patients With Locally Advanced or Metastatic Cancers
Exploratory Clinical Study on Memory NK Cell Therapy for Advanced Metastatic Solid Tumors
A Phase Ia/ Ib Study of HS387 in Subjects With Advanced Solid Tumors
Study of SC-102 in Patients With Advanced Solid Tumors
AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Participants With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent Therapy
An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers
A Study of Investigational Drug CFI-402257 in Patients With Advanced Solid Tumors
A Study of BMS-863233 in Patients With Advanced and/or Metastatic Solid Tumors
Study ADI-PEG 20 Plus Pembrolizumab in Advanced Solid Cancers
Study of SRF231 in Patients With Advanced Solid and Hematologic Cancers
A Study of the mTOR Inhibitor Rapamycin (Rapamune, Sirolimus) in Combination With Abraxane in Advanced Solid Cancers
Pharmacokinetic Study of CKD-810 and Taxotere to Treat Patient With Advanced Solid Cancer
Opioid Rotation Versus Combination for Chronic Uncontrolled Cancer Pain